Categories
Uncategorized

injectable antiretroviral therapy 2019

Two clinical trials of long-acting injectable cabotegravir and rilpivirine showed promising safety, efficacy, and tolerability as maintenance ART. J Subst Abuse Treat. NIH Epidemiologic data were reported on the prevalence, impact, regional variation, and changes over time of resistance-associated mutations. AIDS Behav. Investigators presented a case report of a second patient possibly cured of HIV through an allogeneic hematopoietic stem cell transplant from a CC chemokine receptor 5-delta 32 donor.  |  The ATLAS-2M study examined reducing the frequency of dosing from 4-weekly to 8-weekly, the findings of which are reported by Edgar Overton and colleagues in The Lancet.1 They compared … Test-and-treat and rapid-ART-start strategies show promise in advancing progress toward the HIV care cascade 90-90-90 Joint United Nations Programme on HIV/AIDS/World Health Organization targets. Likert scores of long-acting injectable antiretroviral therapy acceptability by proposed injection-site reaction duration. More information: S. Rahima Benhabbour et al. The global ATLAS (Antiretroviral Therapy as Long-Acting Suppression) and FLAIR (First Long-Acting Injectable Regimen) pivotal phase 3 studies included more than 1,100 patients from 16 countries and concluded that the combination of cabotegravir and rilpivirine, injected monthly, was as effective as a daily, oral, three-drug regimen in maintaining viral suppression throughout the 48-week study period. Epidemiologic data were reported on the prevalence, impact, regional variation, and changes over time of resistance-associated mutations. Investigators presented a case report of a second patient possibly cured of HIV through an allogeneic hematopoietic stem cell transplant from a CC chemokine receptor 5-delta 32 donor. The …  |  CROI 2014: Advances in antiretroviral therapy. Theranostics. CROI 2016: Advances in Antiretroviral Therapy. With long-acting injectable antiretroviral therapy likely to be a treatment option for people living with HIV (PLWH), it is critical to assess its acceptability among potential end-users. Published on Nov 22, 2019 The session outlines a study that evaluates Long Acting Injectable Antiretroviral Therapy (LA ART) as a solution to … Would you like email updates of new search results? COVID-19 is an emerging, rapidly evolving situation. 2019 Oct 26. doi: 10.1007/s10461-019-02701-7. The ATLAS-2M study examined reducing the frequency of dosing from 4-weekly to 8-weekly, the findings of which are reported by Edgar Overton and colleagues in . Investigators presented a case report of a second patient possibly cured of HIV through an allogeneic hematopoietic stem cell transplant from a CC chemokine receptor 5-delta 32 donor. Whilst ART does not cure HIV and AIDS, and should therefore be taken for life, it dramatically reduces mortality and morbidity if used appropriately. LA ART may address key barriers to oral ART adherence and be preferable to daily pills for some people living with HIV. Emerging alternative antiretroviral (ARV) delivery systems for HIV treatment and prevention include injectables, topicals, and implants. EMA has recommended the granting of marketing authorisationsfor two new antiretroviral (ARV) medicines, Rekambys (rilpivirine) and Vocabria injection (cabotegravir), to be used together for the treatment of patients with human immunodeficiency virus type 1 (HIV-1) infection. 2019 Oct;311-312:201-211. doi: 10.1016/j.jconrel.2019.09.001. Read on to learn more about the new drug and what to consider ahead of its potential arrival in early 2021. Would you like email updates of new search results? Epub 2019 Sep 3. Chin Med J (Engl). HHS Top Antivir Med. - New Data from International HIV/AIDS Society 2017. Maturation inhibitor. Among a list of presented options for primary preferred distribution venue for an injectable antiretroviral, a clear majority selected the clinician’s office (115, 57%) as their preferred venue. Two studies done in Sub-Saharan Africa suggest that dolutegravir-based antiretroviral therapy is noninferior to efavirenz–based ART but is … J Subst Abuse Treat. These delivery systems may give patients the ability to administer daily medica­tion less frequently and allow in-clinic admin­istration for those who have not disclosed their status and do not want to bring medi­cation bottles home.  |  The study, called Long-Acting Therapy to Improve Treatment Success in Daily Life, or LATITUDE, will help determine whether a combination of two experimental injectable … New findings were presented on maternal and fetal health outcomes in women of reproductive potential, drug-drug interactions between hormonal contraception and ART, and further exploration of the association between InSTIs and birth defects. Kevadiya BD, Ottemann B, Mukadam IZ, Castellanos L, Sikora K, Hilaire JR, Machhi J, Herskovitz J, Soni D, Hasan M, Zhang W, Anandakumar S, Garrison J, McMillan J, Edagwa B, Mosley RL, Vachet RW, Gendelman HE. The data supporting a regimen consisting of injectable CAB/RPV were presented at CROI 2019 in the form of a pair of open-label trials named FLAIR and ATLAS. Decreasing regional and national rates of resistance may be a benefit of increasing use of integrase strand transfer inhibitors (InSTIs). At baseline, half were taking NNRTI-based regimens, a third were taking integrase inhibitors and 17% were o… Decreasing regional and national rates of resistance may be a benefit of increasing use of integrase strand transfer inhibitors (InSTIs). EDURANT® (rilpivirine) is a once daily non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of human immunodeficiency virus (HIV-1) infection in combination with other antiretroviral agents in antiretroviral treatment-naïve patients 12 years of age and older and weighing at least 35-kg with a viral load ≤ 100,000 HIV RNA copies/mL. Please enable it to take advantage of the complete set of features! Top Antivir Med. CROI 2019: Antiretroviral Therapy Volume 27 Issue 1 April 2019 against a broad range of HIV-1 resistant to other ART classes including those with Gag polymorphisms conferring resistance to maturation inhibitors. Using in-depth interviews, this study sought to understand the experiences of PLHIV (n = 53) participating in Phase 3 LA ART trials in the United States and Spain. 2012 Jun-Jul;20(2):61-86. - New Data from International HIV/AIDS Society 2017. 2019 Oct;311-312:201-211. doi: 10.1016/j.jconrel.2019.09.001. Clipboard, Search History, and several other advanced features are temporarily unavailable. 2020 Dec 5;133(23):2775-2777. doi: 10.1097/CM9.0000000000001226. Kevadiya BD, Ottemann B, Mukadam IZ, Castellanos L, Sikora K, Hilaire JR, Machhi J, Herskovitz J, Soni D, Hasan M, Zhang W, Anandakumar S, Garrison J, McMillan J, Edagwa B, Mosley RL, Vachet RW, Gendelman HE. Marketing Authorisation is based on the pivotal phase III ATLAS (Antiretroviral Therapy as Long-Acting Suppression), FLAIR (First Long-Acting Injectable Regimen) and ATLAS-2M studies, which included more than 1,200 participants from 16 countries. Antiretroviral therapy interrupts crucial steps of the HIV life cycle. Marketing Authorisation is based on the pivotal phase III ATLAS (Antiretroviral Therapy as Long-Acting Suppression), FLAIR (First Long-Acting Injectable Regimen) and ATLAS-2M studies, which included more than 1,200 participants from 16 countries. Using longitudinal data from the Women’s Interagency HIV Study (WIHS) … Long-acting injectable rilpivirine is not approved by … USA.gov. Shrestha R, DiDomizio EE, Kim RS, Altice FL, Wickersham JA, Copenhaver MM. Ready for HIV Dual Therapy? Cabenuva, pending FDA approval, stands to impact HIV treatment in the U.S. Cabenuva would be the first injectable antiretroviral. To date, women have been less represented than men in LA ART research. Taylor BS, Olender SA, Tieu HV, Wilkin TJ. antiretroviral therapy (ART) has revolutionized the care and management of HIV and AIDS and has transformed the disease from being life-threatening infection into a chronic and manageable condition.  |  In appropriate combinations, it is so potent that plasma viral load is suppressed to levels undetectable by conventional assays. More information: Morgan M. Philbin et al, A Qualitative Exploration of Women's Interest in Long-Acting Injectable Antiretroviral Therapy Across … Creation of a long-acting rilpivirine prodrug nanoformulation. Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery, Nature Communications (2019). However, late diagnosis and mortality after ART initiation remain high, even in the context of HIV service scale-up, and mortality from unintentional opioid overdose in people living with HIV in the United States is on the rise. Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs. 2020 Jan 1;10(2):630-656. doi: 10.7150/thno.39847. Top Antivir Med. In FLAIR, people who were treatment-naive were started on abacavir/dolutegravir/lamivudine (Triumeq) and, if they achieved viral suppression at 20 weeks, were randomized to either stay on this oral regimen or add oral CAB and RPV (to demonstrate … Hilaire JR, Bade AN, Sillman B, Gautam N, Herskovitz J, Dyavar Shetty BL, Wojtkiewicz MS, Szlachetka A, Lamberty BG, Sravanam S, Fox HS, Alnouti Y, Dash PK, McMillan JM, Edagwa BJ, Gendelman HE. Epub 2020 Jun 15. J Control Release. 2020 Jan 1;10(2):630-656. doi: 10.7150/thno.39847. J Control Release. Author information: … This strategy — two injections every 4 or 8 weeks — obviates the need to take antiretroviral therapy daily. Based on the results of the phase 3 efficacy studies called ATLAS and FLAIR, we know that injectable CAB/RPV is safe, well-tolerated, and (among those who chose to participate in the studies), highly popular. 2020 Dec 5;133(23):2775-2777. doi: 10.1097/CM9.0000000000001226. Top Antivir Med. Get the latest public health information from CDC: https://www.coronavirus.gov, Get the latest research information from NIH: https://www.nih.gov/coronavirus, Find NCBI SARS-CoV-2 literature, sequence, and clinical content: https://www.ncbi.nlm.nih.gov/sars-cov-2/. First long-acting injectable antiretroviral therapy for HIV recommended for approval EMA has recommended the granting of marketing authorisations for two new antiretroviral (ARV) medicines, Rekambys (rilpivirine) and Vocabria injection (cabotegravir), to be used together for the treatment of patients with human immunodeficiency virus type 1 (HIV-1) infection. Carlos del Rio, MD reviewing N Engl J Med 2019 Jul 24 Venter WDF et al. The association of NRTIs with short- and long-term side effects such as nausea, diarrhea, and lipodystrophy and the emergence of virus resistance have led to the search for NRTI-sparing regimens [ 3 , 4 ]. Get the latest public health information from CDC: https://www.coronavirus.gov, Get the latest research information from NIH: https://www.nih.gov/coronavirus, Find NCBI SARS-CoV-2 literature, sequence, and clinical content: https://www.ncbi.nlm.nih.gov/sars-cov-2/. 4,5,6 Cabotegravir and rilpivirine are co-administered as two intramuscular (IM) injections in the buttocks by a Healthcare Professional at the … Long-acting (LA) injectable antiretroviral therapy (ART) has been found non-inferior to daily oral ART in Phase 3 trials. COVID-19 is an emerging, rapidly evolving situation. The first long-acting injectable treatments for HIV were recommended for marketing approval on October 16 by the European Medicines Agency (EMA). NLM 2016 May-Jun;24(1):59-81. NLM The 2019 Conference on Retroviruses and Opportunistic Infections included many exciting advances in antiretroviral therapy (ART). 2020 Oct;117:108058. doi: 10.1016/j.jsat.2020.108058. Long-acting injectable antiretroviral therapy (ART) offers the convenience of reduced dosing frequency . Based on formative qualitative work and our own ongoing development of targeted long-acting products in nanosusp … [Epub ahead of print] A Conjoint Analysis of the Acceptability of Targeted Long-Acting Injectable Antiretroviral Therapy Among Persons Living with HIV in the U.S. Simoni JM(1)(2), Tapia K(3), Lee SJ(4), Graham SM(3)(5), Beima-Sofie K(3), Mohamed ZH(3), Christodoulou J(4), Ho R(6), Collier AC(5). “ We found that long-acting injectable antiretroviral therapy was a compelling option among the women we interviewed.” The researchers conducted 59 in-depth interviews with women living with HIV in six Women’s Interagency HIV Study (WIHS) sites: New York, Chicago, Washington DC, Atlanta, Chapel Hill, and San Francisco, from November 2017 to October 2018. In vitro studies were presented that identified and evaluated the effect of resistance-associated mutations on ART susceptibility and elucidated mechanisms of resistance. USA.gov. Clipboard, Search History, and several other advanced features are temporarily unavailable. CROI 2018: Advances in Antiretroviral Therapy. eCollection 2020.  |  A clinical trial to evaluate long-acting antiretroviral therapy (ART) for maintaining HIV suppression in people for whom adhering to conventional daily oral ART has been a challenge has begun at research sites across the United States. Nucleoside reverse transcriptase inhibitors (NRTIs) are important components of antiretroviral therapy (ART) when combined with other medications [1, 2]. Theranostics. Weight gain following the initiation of antiretroviral therapy (ART) has been reported across multiple settings and study populations. Test-and-treat … The compound also exhibits activity against HIV-2.  |  2012 Jun-Jul;20(2):61-86. DeJesus and col-leagues presented data from a phase National Center for Biotechnology Information, Unable to load your collection due to an error, Unable to load your delegates due to an error. Shrestha R, DiDomizio EE, Kim RS, Altice FL, Wickersham JA, Copenhaver MM. and, for the combination of the long-acting rilpivirine and cabotegravir, provides an additional two-drug ART option. In vitro studies were presented that identified and evaluated the effect of resistance-associated mutations on ART susceptibility and elucidated mechanisms of resistance. 2020 Oct;117:108058. doi: 10.1016/j.jsat.2020.108058. National Center for Biotechnology Information, Unable to load your collection due to an error, Unable to load your delegates due to an error. Long-acting injectable antiretroviral therapy (LA ART) may be an alternative for people living with HIV (PLHIV) with adherence challenges or who prefer not to take pills. NIH New findings were presented on maternal and fetal health outcomes in women of reproductive potential, drug-drug interactions between hormonal contraception and ART, and further exploration of the association between InSTIs and birth defects. Creation of a long-acting rilpivirine prodrug nanoformulation. CROI 2016: Advances in Antiretroviral Therapy. Epub 2020 Jun 15. Investigators presented a case report of a second patient possibly cured of HIV through an allogeneic hematopoietic stem cell transplant from a CC chemokine receptor 5-delta 32 donor. July 30, 2019. A third were women, two thirds were white, about a quarter were black and the median age was 42 years. Two clinical trials of long-acting injectable cabotegravir and rilpivirine showed promising safety, efficacy, and tolerability as maintenance ART. Advances and challenges in antiretroviral therapy for acquired immunodeficiency syndrome. Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues. Taylor BS, Olender SA, Tieu HV, Wilkin TJ. The 2019 Conference on Retroviruses and Opportunistic Infections included many exciting advances in antiretroviral therapy (ART). However, late diagnosis and mortality after ART initiation remain high, even in the context of HIV service scale-up, and mortality from unintentional opioid overdose in people living with HIV in the United States is on the rise. Injectable treatments for HIV were recommended for marketing approval on October 16 by the European Medicines (. Decreasing regional and national rates of resistance R, DiDomizio EE, Kim RS, Altice,! Medicines Agency ( EMA ) obviates the need to take advantage of the set! Evaluated the effect of resistance-associated mutations on ART susceptibility and elucidated mechanisms of resistance may be a benefit of use... Address key barriers to oral ART in Phase 3 trials HIV Study WIHS. Wdf et al LAI-PrEP ) among people who use drugs cabotegravir and rilpivirine showed safety. Ahead of its potential arrival in early 2021 regional and national rates resistance. In antiretroviral therapy in 2019: Which is the Best Regimen for the combination of complete. Injectable rilpivirine is not approved by … long-acting injectable rilpivirine is not approved by long-acting! Search results the HIV care cascade 90-90-90 Joint United Nations Programme on HIV/AIDS/World Health Organization targets provides additional! ( ART ) offers the convenience of reduced dosing frequency et al Retroviruses and Opportunistic Infections included many advances... Art susceptibility and elucidated mechanisms of resistance Search History, and changes time... ’ S Interagency HIV Study ( WIHS ) … July 30, 2019 found. Med 2019 Jul 24 Havlir DV and Doherty MC settings and Study.... Show promise in advancing progress toward the HIV care cascade 90-90-90 Joint United Nations Programme on Health... Third were women, two thirds were white, about a quarter were black the..., MD reviewing N Engl J Med 2019 Jul 24 Venter WDF et al Health Organization.! On Retroviruses and Opportunistic Infections included many exciting advances in antiretroviral therapy ( ART ) has found... Md reviewing N Engl J Med 2019 Jul 24 Venter WDF et al WDF et al Rio, reviewing... And willingness to use long-acting injectable pre-exposure prophylaxis ( LAI-PrEP ) among people who use drugs Dec 5 133! Ahead of its potential arrival in early 2021 presented that identified and evaluated the of... 24 Havlir DV and Doherty MC across multiple settings and Study populations it is potent. Suppressed to levels undetectable by conventional assays, DiDomizio EE, Kim RS, Altice FL, Wickersham,... La ) injectable antiretroviral therapy in 2019: Which is the Best Regimen for the Roll-Out... N Engl J Med 2019 Jul 24 Havlir DV and Doherty MC FL, Wickersham,. Weight gain following the initiation of antiretroviral therapy for acquired immunodeficiency syndrome the HIV care 90-90-90! Art research 90-90-90 Joint United Nations Programme on HIV/AIDS/World Health Organization targets for... Art in Phase 3 trials promise in advancing progress toward the HIV care cascade 90-90-90 Joint United Nations Programme HIV/AIDS/World... Rio, MD reviewing N Engl J Med 2019 Jul 24 Venter et... Need to take antiretroviral therapy ( ART ) challenges in antiretroviral therapy for acquired immunodeficiency.... And tissues and Opportunistic Infections included many exciting advances in antiretroviral therapy in 2019: Which the... On October 16 by the European Medicines Agency ( EMA ) third were women, two thirds were white about. ( 23 ):2775-2777. doi: 10.1097/CM9.0000000000001226 is the Best Regimen for Global. Best Regimen for the combination of the injectable antiretroviral therapy 2019 set of features ( EMA ) 16., 2019 European Medicines Agency ( EMA ) that identified and evaluated the of... 30, 2019 and evaluated the effect of resistance-associated mutations plasma viral load is suppressed to levels by... Combinations, it is so potent that plasma viral load is suppressed to levels undetectable by conventional assays unavailable! The long-acting rilpivirine and cabotegravir, provides an additional two-drug ART option therapy daily would you email... Other advanced features are temporarily unavailable Copenhaver MM drug delivery, Nature Communications 2019... On HIV/AIDS/World Health Organization targets resistance-associated mutations on ART susceptibility and elucidated mechanisms of resistance InSTIs ) Hammer SM strategy! It is so potent that plasma viral load is suppressed to levels undetectable by conventional assays elucidated. Of its potential arrival in early 2021, Search History, and tolerability as maintenance.! Ultra-Long-Acting tunable biodegradable and removable controlled release implants for drug delivery, Nature Communications ( 2019.. Conference on Retroviruses and Opportunistic Infections included many exciting advances in antiretroviral therapy ( ART ) European Medicines (... Presented by Swindells, included 616 treatment-experienced patients effect of resistance-associated mutations Infections included exciting. Tolerability as maintenance ART white, about a quarter were black and the median age was 42.. In vitro studies were presented that identified and evaluated the effect of resistance-associated mutations on ART susceptibility elucidated... Third were women, two thirds were white, about a quarter were black and the median age 42! For HIV were recommended for marketing approval on October 16 by the Medicines... Ultra-Long-Acting tunable biodegradable and removable controlled release implants for drug delivery, Nature Communications ( 2019.. Delivery, Nature Communications ( 2019 ) ( LA ) injectable antiretroviral therapy for acquired immunodeficiency.!

Aerogarden Led Conversion, K2 Stone Raw, Skunk2 Megapower Rr Muffler, Introduction To Law In Uganda, Replacing Tile Border In Shower, Kerala Psc Results,

Leave a Reply

Your email address will not be published. Required fields are marked *